Advanced Apheresis Technologies - Major Leaders | Global Industry Dynamics

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Critical questions answered by this Study: 

# Where will these developments take the industry in the mid-to-long term?

# Who are the major end users in the apheresis market, and what are the benefits they avail by implementing apheresis technology?

# What are the recent trends in the apheresis market?

# What are the major market dynamics and their impact on overall market growth?

# What is the global scenario of the apheresis market?

The global apheresis market is expected to reach USD 2.7 billion by 2025 from an estimated value of USD 1.7 billion in 2019, growing at a CAGR of 8.1% during the forecast period.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=950

The market for apheresis is primarily driven by the rising prevalence of chronic diseases and the growing number of trauma and injury cases, the increasing demand for source plasma from biopharmaceutical companies, the rising demand for blood components and growing concerns regarding blood safety, the increase in the number of complex surgical procedures, and the favorable reimbursement for apheresis procedures.

However, the high cost of apheresis devices & therapeutic apheresis procedures and installation of apheresis devices through the rental model, fewer blood donations using apheresis due to lack of awareness, and the stringent donor recruitment criteria are factors expected to limit market growth to a certain extent in the coming years.

Objectives of the Study:

# To define, describe, and forecast the global apheresis market by product, technology, application, procedure, end user, and region

# To provide detailed information about the factors influencing the market growth (drivers, restraints, opportunities, and challenges)

# To analyze micro markets with respect to individual growth trends, prospects, and contributions to the overall market

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players

# To forecast the size of the apheresis market in five regions (along with major countries)—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.

# To profile key players in the apheresis market and comprehensively analyze their core competencies and market shares

# To track and analyze competitive developments such as acquisitions; new product launches; collaborations, partnerships, and agreements; and R&D activities of the leading players in the global apheresis market

North America accounted for the largest market share in 2018

North America accounted for the largest share of the apheresis market in 2018, followed by Europe. The large share of this region can be attributed to easier accessibility to advanced blood collection technologies, the presence of established healthcare infrastructure, and the increasing presence of leading apheresis companies in the country.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=950

Recent Developments:

# In July 2019, Baxter International Inc. (US) launched the PrisMax system in the US.

# In June 2019, Toray Medical Co. Ltd. (Japan) launched the TORAMYXIN device in the European region.

# In October 2019, Terumo BCT (US) collaborated with the UniCAR-Therapy Bio-Medicine Technology Co. (China). This collaboration aimed at advancing CAR T-cell therapies by creating a new Shanghai Center of Excellence. This development also helped Terumo widen its applications of apheresis and leukapheresis procedures.

# In August 2017, Fresenius Medical Care (Germany) acquired NxStage Medical, Inc. (US). This acquisition enabled Fresenius Medical Care to further expand its presence in the renal care and critical care area.

The prominent players in this market are Terumo BCT, Inc. (US), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Asahi Kasei Medical Co. Ltd. (Japan), B. Braun Melsungen AG (Germany), Baxter International Inc. (US), Cerus Corporation (US), Kaneka Corporation (Japan), Kawasumi Laboratories, Inc. (Japan), Nikkiso Co., Ltd. (Japan), Macopharma SA (France), Miltenyi Biotec (Germany), Otsuka Holdings Co. Ltd. (Japan), Medica S.p.A. (Italy), Mallinckrodt plc (Ireland), Medicap Clinic GmbH (Germany), Lmb Technologies GmbH (Germany), Bioelettronica (Italy), Infomed (Switzerland), Cytosorbents Corporation (US), and Toray Medical Co. Ltd. (Japan), among other key players.

Cell Isolation - Emerging Markets to Offer Major Growth Opportunities

Growth in the cell isolation market is mainly driven by the growing government funding for cell-based research, increasing number of patients suffering from cancer and infectious diseases, technological advancements, and the growing focus on personalized medicine.

The study involved four major activities to estimate the current market size for the global cell isolation market. Exhaustive secondary research was done to collect information on the market and its different subsegments.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Then, both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=103931479

Market Size Estimation:

Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell isolation market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

# The key players in the industry and markets have been identified through extensive secondary research.

# The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes.

# All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Biotechnology & biopharmaceutical companies to hold the largest share of the market during the forecast period.

Based on end users, the cell isolation market is segmented into research laboratories & institutes, hospitals & diagnostic laboratories, biotechnology & biopharmaceutical companies, and other end users. The biotechnology & biopharmaceutical companies segment accounted for the largest market share in 2018. The large share of this segment is attributed to the widespread adoption of advanced instruments in cell-based experiments and cancer research in biotechnology & biopharmaceutical companies and the increasing number of R&D facilities globally.

Recent Developments:

# In 2017, Beckman Coulter launched CytoFLEX Flow Cytometry.

# In 2017, Miltenyi Biotec launched MultiMACS X Device

# In 2017, MilliporeSigma entered into a partnership with Public Health England to distribute the European Bank of Induced Pluripotent Stem Cells (EBiSC)

# In 2016, Becton, Dickinson and Company (BD) launched BD FACSymphony

North America held the largest share of the market in 2018.

The cell isolation market is segmented into four major geographic segments North America, Europe, Asia Pacific, and the Rest of the World. In 2018, North America commanded the largest share of the cell isolation market, followed by Europe. The large share of the North American market is attributed to technological advancements, growth in the biotechnology and pharmaceutical industries, increasing prevalence of chronic and infectious diseases, and higher investments in cell-based research in the region.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=103931479

The key strategies followed by most companies in the cell isolation market are product launches, expansions, agreements, and acquisitions to achieve growth in the cell isolation market. The product launches accounted for the largest share of the overall growth strategies adopted from 2015 to 2018.

Key questions addressed in the report:

# What are the growth opportunities offered by the cell isolation market across major regions in the next five years?

# Emerging countries have immense opportunities for growth in the cell isolation market. Will this scenario continue during the next five years?

# How will advancements in products offered by various companies affect the market scenario in the mid- to long-term?

# What are the new trends and advancements in the cell isolation market?

The major players in the cell isolation market are Beckman Coulter (US), Becton Dickinson and Company (US), GE Healthcare (US), Merck KgaA (Germany), Miltenyi Biotec (Germany), pluriSelect (Germany), STEMCELL Technologies Inc. (Canada), Terumo BCT (US), Thermo Fisher Scientific (US), and Bio-Rad Laboratories Inc. (US).

Stem Cell Banking Market - Emerging Industry Innovations & Future Forecasts

The global stem cell banking market is projected to reach USD 9,415.4 million by 2023 from USD 6,290.6 million in 2018, at a CAGR of 8.4% from 2018 to 2023.

Factors such as the growing awareness on the therapeutic potential of stem cells; development of novel technologies for stem cell preservation, processing and storage; increase in hematopoietic stem cell transplantation (HSCT) procedures; and increasing investments in stem cell-based research are driving the growth of the stem cell banking market.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=220680183

Recent Developments:

# In 2017, Life Cell International (India), launched upgraded and enhanced its umbilical cord collection kit

# In 2017, Vita34 AG (Germany) acquired Seracell Pharma AG (Germany) to strengthen its position in the German stem cell banking market.

# In 2016, StemCyte India Therapeutics Pvt. Ltd. (India), a subsidiary of StemCyte (US) received accreditation from The Foundation for the Accreditation of Cellular Therapy (FACT) for both public and private stem cell banking services.

# In 2015, Cord Blood Registry (CBR) Systems (US) entered into a collaboration agreement with New York Stem Cell Foundation (US) to develop induced pluripotent stem cells from umbilical cords

Restraint: High operational costs of stem cell banking

Cell banks, tissue banks, and biobanks incur significant expenditure during the sample processing, quality testing, and sample preservation and storage processes. This does not include spending on the purchase and maintenance of premium-priced instruments, reagents, and consumables. This results in high operational costs for service providers. 

Moreover, increasingly stringent and mandatory regulatory requirements related to stem cell preservation and banking—as well as the costly licensing/approval process for the establishment of stem cell banks in developed nations—are expected to further contribute to the overall operational costs for stem cell banking service providers.

Key questions addressed in the report:

# What are the growth opportunities related to stem cell banking market across major regions in the future?

# Emerging countries have immense opportunities for the growth and adoption of stem cell banking. Will this scenario continue in the next five years?

# What are the various types of stem cell banking services and their market share in the overall market?

# What are the new trends and advancements in the applications segment?

North America is expected to dominate the stem cell banking market in 2019

Geographically, the market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America is expected to account for the largest share in 2019. The expanding network of stem cell banking services across the region, ongoing approval of stem cell lines for disease treatment (especially for hematopoietic & autoimmune disorders), recent technological advancements in the field of stem cell collection and preservation techniques, and rising public-private investments for stem cell researches are driving the growth of the stem cell banking market in North America.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=220680183

The major players in the market include Cord Blood Registry (CBR) Systems (US), Cordlife Group Limited (Singapore), Cryo-Cell International (US), ViaCord (US), Cryo-Save AG (Netherlands), LifeCell International (India), StemCyte (US), Global Cord Blood Corporation (China), Smart Cells International (UK), Vita34 AG (Germany), and CryoHoldco (Mexico); among others.

Surgical Imaging Industry - Emerging Markets to Offer High Growth Opportunities

The following are the major objectives of the study:

# To describe and forecast the surgical imaging market, in terms of value, by technology, application, and region

# To describe and forecast the market, by region–Asia Pacific (APAC), Europe, North America, and Rest of the World (RoW) along with their respective countries

# To provide detailed information regarding major factors influencing market growth (drivers, restraints, opportunities, and challenges)

# To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market

# To study the complete value chain of surgical imaging

# To analyze opportunities in the market for stakeholders by identifying the high-growth segments of the surgical imaging ecosystem

# To strategically profile key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing competitive landscape for market leaders

# To analyze strategic approaches such as partnerships, agreements, alliances, collaborations, product launches, expansions, and acquisitions in the market

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=210534462

By application, the orthopedic and trauma surgeries segment is expected to command the largest share of the market in 2017

On the basis of application, the market has been segmented into orthopedic and trauma surgeries, neurosurgeries, cardiovascular surgeries, gastrointestinal surgeries, and other applications (urology and endobronchial & thoracic surgery). The orthopedic and trauma surgeries segment is expected to command the largest share of the market in 2017. The large share and high growth of this segment can be attributed to factors such as increasing popularity of minimally invasive procedures in orthopedic and trauma surgeries and the advantage of 3D navigation with the use of C-arms.

North America to dominate the market in 2017

North America is expected to account for the largest share of the surgical imaging market in 2017, followed by Europe, Asia Pacific (APAC), and the Rest of the World. The large share of this region can be attributed to a rising number of overuse sports injuries, and rising prevalence of CVD, along with the increasing number of cardiac arrest cases, and increase in the number of minimally invasive procedures performed in Canada. However, Asia Pacific is expected to register the highest CAGR of 7.1% during the forecast period, owing to the rapid growth in geriatric population in Japan, healthcare reforms in China, improving healthcare infrastructure in India, and rising number of orthopedic and CVD procedures in Australia.

Target Audience:

# C-arms manufacturers and distributors

# Healthcare institutions (hospitals, medical schools, group practices, individual surgeons, and governing bodies)

# Medical device vendors/service providers

# Research institutes

# Niche companies manufacturing imaging systems

# Research and consulting firms

# Venture capitalists

GE Healthcare (US), Koninklijke Philips (Netherlands), Siemens (Germany), and Ziehm Imaging (Germany) are the key players in the surgical imaging market. Other players involved in this market are Hologic (US), Shimadzu Corporation (Japan), OrthoScan (US), Medtronic (US), Toshiba Medical Systems Corporation (Japan), GENORAY (South Korea), Eurocolumbus (Italy), and Allengers Medical Systems (India).

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=210534462

Major Market Developments:

# In 2017, Koninklijke Philips partnered with Government of Kenya and the United Nations to Establish the SDG (Sustainable Development Goals) Partnership Platform in Kenya to make primary healthcare more accessible

# In 2017, Koninklijke Philips established its first innovation center in Moscow, Russia

# In 2017, Siemens Received US FDA approval for its Cios Fusion, Cios Connect, and Cios Select

# In 2017, Ziehm Imaging Launched the new version of Ziehm Vision FD with a complementary metal oxide semiconductor (CMOS) flat-panel detector and a new CMOS flat-panel detector which allows for display of smaller pixels in the same quality

# In 2016, Shimadzu Corporation established an indirectly-owned subsidiary—Shimadzu Malaysia Sdn Bhd.

Drug Discovery Services - Emerging Technological Advancements & Future Forecasts

The study involved four major activities in estimating the current size of the drug discovery services market. Exhaustive secondary research was done to collect information on the market and its different subsegments.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

Recent Developments:

# In 2019, Charles River (US) and CHDI Foundation, Inc. (US), Extended collaboration on drug discovery and development for Huntington’s Disease by five years

# In 2019, Laboratory Corporation of America Holdings’s (US) opened the Covance Drug Development segment opened a new R&D Center in Shanghai, China—its largest facility in the Asia Pacific. This will help the company to grow its business in China and the APAC.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=138732129

The global drug discovery services market size is projected to reach USD 19.1 billion by 2025 from USD 10.7 billion in 2020, at a CAGR of 12.1% from 2020 to 2025, the market will be driven by growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, thus necessitating increasing demand for outsourcing analytical testing and clinical trial services.

Initiatives for research on rare diseases and orphan drugs, and focus on drug discovery are driving the growth of the global drug discovery services industry. Growth in biologics, patent expiries and emerging economies are expected to provide a wide range of growth opportunities for players in the market.

North America is expected to command the largest share of the drug discovery services market in 2020.

Based on the region, the global drug discovery services market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. In 2020, North America is expected to command the largest share of the drug discovery services market. The large share of this market segment can be attributed majorly to the presence of well-established CROs, rising R&D expenditure by pharmaceutical & biopharmaceutical companies, and the availability of latest techniques, instruments, and facilities for drug discovery research.

Key Questions Addressed in the Report:

# What are the growth opportunities in the market across major regions in the future?

# Emerging countries have immense opportunities for the growth and adoption of drug discovery services. Will this scenario continue during the next five years?

# What are the various drug discovery services and their respective market shares in the overall market?

# What are the new trends and advancements in the market?

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=138732129

The major players operating in this market Laboratory Corporation of America Holdings (US), Albany Molecular Research, Inc. (US), Charles River Laboratories International, Inc. (US), Evotec SE (Germany), Eurofins Scientific (Luxembourg), WuXi AppTec (China), GenScript Biotech Corporation (China), Thermo Fisher Scientific, Inc. (US), Pharmaceutical Product Development, LLC (US), Syngene International Ltd. (India), and Selvita S.A. (Poland) among others.

Delivery of Biologics Through the Transdermal Route - A Major Shift in the Global Topical Drug Delivery Industry

This study involved the extensive use of both primary and secondary sources. The research process involved the study of various factors affecting the industry to identify the segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Market Size Estimation:

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (segmental analysis of major segments) and top-down approach (assessment of utilization/adoption/penetration trends, by product, route of administration, facility of use, and region).

Data Triangulation:

After arriving at the market size, the market was divided into several segments and sub-segments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments & sub-segments.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=124871717

North America to dominate the Topical Drug Delivery market during the forecast period

In 2018, North America dominated the Topical Drug Delivery market, followed by Europe. The growing prevalence of skin diseases coupled with the development of the technologically advanced topical and transdermal products in the region are the factors propelling the growth of the market in the region. 

For instance, in February 2018, Scilex Pharmaceuticals (US), launched ZTlido (Lidocaine Topical System) 1.8% patches for the management of pain in the US. Similarly, in December 2017, Aclaris Therapeutics Inc. (US), launched ESKATA (Hydrogen Peroxide) Topical Solution, 40% (w/w) for the treatment of raised seborrheic keratosis in the US market.

Recent Developments:

# In April 2019, Crescita Therapeutics signed an out-licensing agreement with Cantabria labs for the sales and distribution of its topical Pliaglis formulation in Italy, Portugal, France, and Spain.

# In November 2018, Bausch Healthcare expanded its manufacturing facility in Rochester (Ireland) to support and fulfill the demand of its topical eye health products.

Prominent players in the Topical Drug Delivery market are Novartis AG (Switzerland), Johnson & Johnson (US), Bausch Health Companies (Canada), Nestle SA (Switzerland), GlaxoSmithKline (UK), Mylan (US), Merck & Co (US), Bayer AG (Germany), Hisamitsu Pharmaceutical (Japan), Cipla Ltd (India), Crescita Therapeutics Inc. (Canada), and Glenmark Pharmaceuticals (India).

Critical questions answered in the report:

# How will the current technological trends affect the market in the long term?

# What are the reasons contributing to the growth of the semi-solid market?

# Which regions are likely to grow at the highest CAGR?

# What are the challenges hindering the adoption of topical drug delivery devices?

# What are the growth strategies being implemented by major market players?

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=124871717

Protein Assays Market - Expected Industry Growth in the Near Future

Target Audience for this Report:

# Protein assay manufacturers and vendors

# Distributors of protein assays

# Various research and consulting companies

# Associations related to pharmaceutical and biotechnological research

This report provides a detailed overview of the major drivers, restraints, challenges, opportunities, and strategies impacting the protein assays market, along with revenue estimates & forecasts and market share analysis.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=93720547

Based on end user, the protein assays market is segmented into pharmaceutical & biotechnology companies, clinical laboratories, hospitals, academic research institutes, and other end users. In 2017, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the market. This growth can be attributed to the increasing drug development in the life science industry.

The global protein assays market is expected to reach USD 2.41 Billion by 2022 from USD 1.42 Billion in 2017, at a CAGR of 11.1% from 2017 to 2022. The increasing pharmaceutical & biotech R&D expenditure and favorable government funding scenario for proteomics research are the major factors driving the growth of this market.

Restraints:

# High Cost of Multiplex Assay Equipment

# Sequestration Cuts in the U.S.

Opportunities:

# Emerging Markets

# Biomarker Identification

Challenges:

# Dearth of Skilled Professionals

# Issues Related to the Development of Protein Assays for Various Disease Types

On the basis of region, the global protein assays market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the highest CAGR during the forecast period. The growth in this region is primarily driven by the increasing pharmaceutical and biotechnology R&D expenditure and availability of government funding for life sciences research.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=93720547

Some of the major players operating in the protein assays market are Thermo Fisher Scientific (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Merck KGaA (Germany), Cell Signaling Technology, Inc. (U.S.), General Electric Company (U.S.), and PerkinElmer Inc. (U.S.).

The growth of the protein assays market can be attributed to the increasing pharmaceutical & biotech R&D expenditure and favorable government funding scenario for proteomics research. Based on the analysis of strategic developments undertaken by market players between 2014 and 2017, the key strategy followed by most companies in the market is expansions and agreements, partnerships, and collaborations.

Poultry Diagnostics Market - Future Growth Boosters | Emerging Trends

Years considered for this report:

# 2016 – Base Year

# 2017 – Estimated Year

# 2022 – Projected Year

The poultry diagnostics market is expected to reach USD 495.3 Million by 2022 from an estimated USD 300.6 Million in 2017, at a CAGR of 10.5%.

The growth of the market during the forecast period is mainly driven by the increase in the avian diseases outbreak and zoonotic diseases, increasing adoption of vaccinations, diagnostic monitoring of birds for the presence of disease pathogens, and the rising consumer concerns regarding food safety. However, high cost of production, lack of animal healthcare awareness, and trade disputes such as import bans are expected to restrain the overall market growth, to a certain extent, during the forecast period.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=134560458

Key Market Growth Restraint:

# High Poultry Production Costs

Key Market Opportunity:

# Untapped Emerging Markets

Key Challenge:

# Lack of Animal Health Awareness in Emerging Markets

Industry Trends:

# Outsourcing Diagnostic Testing Services to Reference Labs

# Rising Number of Research Collaborations

Geographically, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The Asia-Pacific region is expected to witness the highest growth during the forecast period. Growth in this region can be attributed to the large livestock population in this region, growing demand of poultry-derived food products, increasing awareness about animal health, and growing per capita animal health expenditure, especially in India and China.

Target Audience:

# Veterinary diagnostics manufacturers

# Veterinary diagnostics distributors

# Animal health research and development (R&D;) companies

# Veterinary reference laboratories

# Government associations

# Market research and consulting firms

# Venture capitalists and investors

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=134560458

Some of the prominent players in the poultry diagnostics market are IDEXX Laboratories, Inc. (U.S.), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific Inc. (U.S.), Zoetis, Inc. (U.S.), GD Animal Health (Netherlands), IDVet (France), AffiniTech, LTD. (U.S.), AgroBioTek Internacional (Honduras), BioNote, Inc. (South Korea), BioChek (Netherlands), Boehringer Ingelheim (Germany), MEGACOR Diagnostik GmbH (Germany), and BioinGentech Biotechnologies, Inc. (Chile).

The global poultry diagnostics market is consolidated in nature with the top five players accounting for nearly 65%-70% of the market share in 2016. However, there are numerous small players in the market operating at the regional level.

Environmental Testing Equipment Industry - Introduction of Innovative Rapid Technologies

The study involved four major activities to estimate the current market size for environmental testing equipment. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across value chain through primary research. 

Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter market breakdown and data triangulation was used to estimate the market size of segments and subsegments

Key questions addressed by the report:

# Which of the product segment will dominate the global market in the next five years?

# Emerging countries have immense opportunities for the growth and adoption of environmental testing equipment, will this scenario continue in the next five years?

# Increasing environmental awareness in the emerging market is impacting the growth for developed markets. How will the pricing difference impact the overall market?

# What are the upcoming technologies in the global market?

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=149706080

The global environmental testing equipment market is expected to reach USD 2.9 billion by 2023 from USD 2.1 billion in 2018, at a CAGR of 7.1%. Growth in the environmental testing equipment market is mainly driven by factors such as the rising levels of environmental pollution worldwide, increasing government regulations and initiatives for environmental protection, privatization of environmental testing services, and increasing focus on wastewater treatment.

Report Objectives:

# To define, describe, and measure the global environmental testing equipment analysis market by product, application, and region.

# To provide detailed information about major factors influencing market growth (such as drivers, restraints, growth opportunities, and challenges).

# To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the global environmental testing equipment analysis market.

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.

# To forecast the size of the market in North America, Europe, Asia Pacific (APAC), and the Rest of the world (RoW).

# To strategically analyze the market structure and profile key players and their core competencies3 in the global environmental testing equipment analysis market.

# To track and analyze competitive developments such as product launches, acquisitions & expansions, partnerships, agreements & collaborations, in the environmental testing equipment analysis market.

North America is expected to dominate the environmental testing equipment market during the forecast period

Geographically, North America is expected to dominate the global environmental testing equipment market in 2018, while the Asia Pacific region is expected to register the highest CAGR during the forecast period. The high growth in this region can be attributed to the rising outdoor air pollution levels, the availability of government funding, and stringent environmental monitoring regulations.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=149706080

The major players operating in the environmental testing equipment market include Agilent Technologies (US), Thermo Fisher Scientific (US), and Shimadzu Corporation (Japan). Other players involved in this market include Waters Corporation (US), Bruker (US), PerkinElmer (US), SCIEX (a subsidiary of Danaher) (US), JEOL (Japan), Analytik Jena (Germany), and Merck KGaA (Germany).

The analysis of market developments between 2016 and 2018 showed that market players adopted growth strategies such as product launches, strategic acquisitions, expansions, partnerships, agreements, and collaborations to strengthen their product portfolios and maintain a competitive position in the environmental testing equipment analysis market.

Recent Developments:

# In March 2018, Agilent established a new logistics hub in Shanghai to enable rapid delivery of the company’s instrument parts, supplies, and consumables to laboratories in China.

# In August 2016, Shimadzu acquired SINC (SINC do Brasil Instrumentaçâo Cientifica Ltda.) to strengthen its analytical and measuring instruments business in Brazil.

Microscope Software Market - Emerging Industry Dynamics

The study involved 4 major activities in estimating the current size of the microscope software market. Exhaustive secondary research was done to collect information on the market as well as its peer and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both the top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.

Recent Developments:

# In 2018, DRVISION technologies partnered with Etaluma systems to provide Aivia image analysis solutions with Etaluma’s microscope systems.

# In 2017, Carl Zeiss collaborated with VIB Bioimaging Core to develop and patent an innovative software-based super-resolution image processing technology.

# In 2017, Carl Zeiss partnered with Glencoe software to extend the open-source Bio-Formats image file conversion library to support whole-slide images compressed with the JPEG XR compression scheme.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=89006739

[106 Pages Report] The microscope software market is projected to reach USD 780 million by 2023 from USD 414 million in 2018, at a CAGR of 13.5%. Growth in this market is driven by the rapid adoption of imaging solutions, the development of new Microscopy methods, and increasing volumes of biological imaging data.

Report Objectives:

# To define, describe, segment, and forecast the microscope software market by application, type, and end user.

# To provide detailed information about the factors influencing market growth (drivers, restraints, opportunities, and challenges).

# To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall market.

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.

# To forecast the size of market segments in North America, Europe, Asia Pacific (APAC), and the Rest of the World (RoW).

# To profile the key players and comprehensively analyze their core competencies in terms of key market developments, product portfolios, and financials.

# To track and analyze competitive developments such as acquisitions, product developments, partnerships, agreements, collaborations, and expansions in the microscope software market

The pharma & biotech industries end-user segment of life sciences microscope software market is projected to occupy the largest share of the market during the forecast period.

Pharma & biotech industries accounted for the largest share of the market in 2017. Microscopy plays a crucial role in pharmaceutical and biotech drug discovery and development. The pharmaceutical industry widely uses microscopy in drug discovery applications, which include drug formulation, toxicology, target identification, and cell culture. This is a key factor driving market growth. Advancements in microscopy techniques such as digitization, live-cell imaging, super-resolution, and high-throughput methods are also generating interest among pharmaceutical and biotechnology companies. This, in turn, will drive the market for this end-user segment.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=89006739

North America is projected to account for the largest share of the microscope software market during the forecast period.

North America is estimated to account for the largest share of the microscope software market in 2017. Factors such as the presence of a strong life sciences industry and a large base of academic and research institutes in the US are driving the growth in this region. Canada is also a potential market for microscopy owing to favorable government support and growing academic excellence in nanotechnology-based R&D programs.

Major vendors in the microscope software market include Danaher (US), Oxford Instruments (US), Zeiss (Germany), Olympus (Japan), Nikon (Japan), and Thermo Fisher Scientific (US).

Key questions addressed by the report:

# Who are the major players in the microscope software market?

# What are the growth trends and the largest revenue-generating regions for microscope software?

# How are microscope software sold to customers?

# What are the major types of microscope software?

# Who are the major end users of microscope software in the life sciences industry?

Bioprocess Validation Market - Emerging Industry Trends & Global Future Forecasts

This study involved the extensive use of primary and secondary sources and involved an in-depth analysis of the various factors affecting the growth of the global bioprocess validation market. Both primary and secondary research was used to identify the segmentation types, trends, key players, key market dynamics, and key player strategies as well as derive the competitive leadership mapping and competitive landscape in this market.

Objectives of the Study:

# To define, describe, and forecast the bioprocess validation services market based on test type, process component, end-user, and region.

# To provide detailed information regarding the factors influencing market growth (such as drivers, restraints, opportunities, challenges, and industry trends)

# To analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall bioprocess validation services market.

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players operating in this market.

# To strategically profile the key players in the bioprocess validation services market and comprehensively analyze their market shares and core competencies

# To strategically analyze five different geographical regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

# To track and analyze competitive developments such as joint ventures & acquisitions; product developments and enhancements; agreements & partnerships; expansions; and funding activities in the bioprocess validation services market.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=39981433

This market is exceeded USD 180 million in 2019 and is projected to be valued over USD 360 million by 2024, at a CAGR of 14.6% during the forecast period. The stringent safety and quality regulations governing product certification and testing across the biopharmaceutical and pharmaceutical industries, high demand for the outsourcing of bioprocess validation services and rising R&D spending in the life science are some of the major factors that are expected to drive the growth of this market during the forecast period.

North America is estimated to be the largest regional market for bioprocess validation

North America is expected to account for the largest share of the bioprocess validation market in 2019, closely followed by Europe. Factors such as the presence of well-established biopharmaceutical industry in the region, high R&D expenditure, presence of leading bioprocess validation service providers, and stringent regulatory requirements for biopharmaceutical production are driving the growth of the bioprocess validation market in North America.

Recent Developments:

# In August 2018, Merck KGaA launched the BioReliance Product Characterization Portfolio to enhance its service portfolio in the bioprocess validation market.

# In March 2017, Toxikon and SG Lab (Italy) entered into a partnership, to extend its analytical and extractable & leachable testing service portfolio to determine the drug integrity in the entire life cycle.

# In January 2019, SGS acquired LeanSis Expertos en Productividad S.L. (Spain). This acquisition provided SGS operational and manufacturing training and capacity building services to over 200 clients across Spain.

# In February 2018, Pall Corporation expanded its Hoegaarden office in Belgium with new R&D center, customer demonstration labs, and manufacturing space. This will help the company to establish its position in the Belgium market.

The prominent players operating in the bioprocess validation market are Merck KGaA (Germany), Sartorius Stedim Biotech (Sartorius AG) (France), Pall Corporation (US), SGS S.A. (Switzerland), Eurofins Scientific (Luxembourg), Cobetter Filtration Equipment Co., Ltd. (China), Toxikon Corporation (US), DOC S.r.l. (Italy), MEISSNER FILTRATION PRODUCTS, INC. (US), and Thermo Fisher Scientific (US).

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=39981433

Critical questions the report answers:

# Where will all these developments take the industry in the medium-to-long-term?

# What are the major trends in bioprocess validation?

# Who are the major end-users of bioprocess validation?

# Which test types are used mainly for bioprocess validation?

# Which process component has a higher adoption rate of bioprocess validation?

Merck KGaA (Germany) is one of the leading players in the global bioprocess validation market. The company’s leading position in this market is attributed to its extensive geographic presence across North America, Europe, Middle East & Africa, and Asia Pacific.

Pall Corporation (US) accounted for the second-largest share of the bioprocess validation market in 2018. The company’s wholly-owned subsidiary offers validation services for single-use and reusable process components used in bioprocessing. The company provides validation services to the biopharmaceutical industry through its strong distribution network across the globe.

Sartorius Stedim Biotech was the third-largest bioprocess validation company in the market in 2018. The company offers validation services; microbiological & physicochemical tests; and extractable & leachable, regulatory compliance, equipment qualification (IQ|OQ and SAT), and testing services for drug development. To build brand loyalty and enhance its brand image, Sartorius Stedim Biotech primarily focuses on supporting multiple country-specific biopharmaceutical manufacturing regulations.

Read More Detailed Information@

https://www.marketsandmarkets.com/Market-Reports/bioprocess-validation-market-39981433.html

Tracheostomy Products Market - Emerging Technological Innovations & Future Forecasts

The study involved four major activities in estimating the current size of the tracheostomy products market. Exhaustive secondary research was carried out to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the size of segments and subsegments.

Report Objectives:

# To define, describe, and forecast the tracheostomy market based on product, technique, end user, region, and country

# To provide detailed information on the major factors influencing market growth (such as drivers, restraints, opportunities, and industry-specific challenges)

# To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and their contributions to the overall tracheostomy market

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players

# To forecast the market value of various segments and sub-segments with respect to five regions—North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

# To profile the key players in the tracheostomy market and comprehensively analyze their global revenue shares and core competencies

# To track and analyze competitive market-specific developments such as product launches, partnerships, expansions, and acquisitions

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=79626751

The tracheostomy products market size is projected to reach USD 220 million by 2024 from USD 179 million in 2019, at a CAGR of 4.2%. The major factors driving the growth of the tracheostomy products market are the availability of clinical evidence for their safety & efficacy and increasing adoption of tracheostomy procedures among medical professionals owing to procedural benefits offered by tracheostomy products. Moreover, the rising demand for home care services is expected to play a significant role in fueling market growth.

Tracheostomy tubes segment accounted for the largest share of the tracheostomy products market, by type, in 2018

The tracheostomy tubes segment held the largest share of the tracheostomy products industry in 2018. The large share of this segment can be attributed to the procedural and technical benefits offered, such as the ability to pass suctioning catheters or fiberoptic devices into the collapsed area, rapid placement, fast lung isolation, and non-requirement for bronchoscopy in placement.

Recent Developments:

# In February 2019, Medtronic Plc entered into a partnership with Medical University of South Carolina (US) for the development of better and affordable healthcare solutions (including tracheostomy procedure for breathing assistance) for patients

# In October 2017, Medtronic Plc established the Chengdu Innovation Center at Singapore for cross-disciplinary clinical training and R&D.

Ciaglia blue rhino tracheostomy segment to register the highest growth in the tracheostomy products market, by technique, during the forecast period

The ciaglia blue rhino tracheostomy segment is expected to grow at the highest CAGR during the forecast period. Growth in this market can primarily be attributed to procedural benefits offered, such as the low risk of damage to the membranous tracheal wall and rapid insertion (owing to the passage of a single dilator). Furthermore, the market growth is driven by favorable reimbursement scenario & medical insurance coverage and the availability of clinical evidence for their safety & efficacy.

Hospitals & surgical centers segment accounted for the largest share of the tracheostomy products market, by the end-user, in 2018

Hospitals & surgical centers were the largest application segment of the tracheostomy products industry, and this trend is expected to continue during the forecast period. A large number of private enterprises are taking steps to cater to the needs of modern, which has resulted in the large share of this segment. Other significant factors include well-equipped state-run healthcare facilities in these regions and growing healthcare consolidation to improve access to healthcare services.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=79626751

Key Questions Addressed by the Report:

# Emerging countries are offering immense opportunities for the growth and adoption of market. Will this scenario continue in the coming years?

# Where will all the advancements in products offered by various companies take the industry in the mid-to-long term?

# What are the various research institutes where tracheostomy products find a high adoption rate?

# What are the new trends and advancements in the market?

# How is the shift in dynamics shaping the future of the market?

North America dominates the tracheostomy products market

The market is segmented into five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest share of the market in 2018. Factors such as the presence of a highly developed healthcare system, an increasing number of emergency department visits, high adoption of innovative tracheostomy devices among medical professionals, and wide availability of advanced tracheostomy devices are driving the market for tracheostomy products in North America.

The major players operating in the tracheostomy products market are Medtronic plc (Ireland), Smiths Group plc (UK), TRACOE Medical GmbH (Germany), Teleflex Incorporated (US), and Fisher & Paykel Healthcare Ltd. (New Zealand). Other prominent players operating in this market include ConvaTec Group (US), Cook Group (US), Troge Medical GmbH (Germany), Well Lead Medical Co., Ltd. (US), Fuji Systems Corporation (Japan), Andreas Fahl Medizintechnik-Vertrieb GmbH (Germany), Xinxiang Huaxi Sanitary Materials Co., Ltd. (China), Medis Medical (Tianjin) Co. Ltd. (China), Boston Medical (US), and Pulmodyne (US).

You Will Find More Detailed Article@

https://www.marketsandmarkets.com/Market-Reports/tracheostomy-product-market-79626751.html

ATP Assay Market - Emerging Industry Trends & Global Future Forecasts

The study involved four major activities in estimating the current size of the ATP assays market. Exhaustive secondary research was conducted to collect information on the market as well as its peer and parent markets. The next step is to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both the top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the sizes of segments and subsegments.

The global ATP assays market size is projected to reach USD 315 million by 2024 from USD 191 million in 2019, at a CAGR of 10.5%. Growth in this market is majorly driven by the increasing demand for ATP assays in pharmaceutical & biotechnology companies, rising investments in pharmaceutical & biotechnology R&D, the increasing prevalence of cancer and other chronic and infectious diseases, and the shift from culture-based tests to rapid tests.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=223438780

The consumables & accessories segment accounted for the largest share of the ATP assays market, by product, in 2018

Based on product, the market is segmented into consumables & accessories and instruments. The consumables & accessories segment accounted for the largest ATP assays market share in 2018. The large share of this segment can be attributed to the high usage of ATP assays for microbial contamination testing and the growing applications of ATP assays in different industries like the food & beverage industry and agriculture industry. The large share of this segment is also supported by the fact that the consumables such as kits & reagents, microplates, and swabs are purchased repeatedly as compared to instruments such as luminometers and spectrophotometers.

By end user, pharmaceutical & biotechnology companies accounted for the largest market share in 2018

Based on end user, the ATP assays market is segmented into pharmaceutical & biotechnology companies, the food & beverage industry, hospitals & diagnostic laboratories, and academic & research institutions. In 2018, the pharmaceutical & biotechnology companies segment accounted for the largest share of the market. ATP assays are emerging as preferred tools for screening potential drug compounds; therefore, many pharmaceutical and biotechnology companies are gradually replacing other in vitro and biochemical assays with cell-based assays, such as ATP assays, in drug discovery. Owing to the increasing adoption of cell-based assays, the use of ATP assay kits is also likely to increase in the coming years.

Recent Developments:

# In March 2019, Promega launched the Water-Glo reagent, which uses bioluminescent technology to measure ATP and is used for monitoring microbial contamination in freshwater, process water, seawater, or wastewater samples.

# In August 2018, Hygiena acquired Biomedal’s Food Safety division. Under this acquisition, the new division will be named Hygiena Diagnóstica España and will provide allergen tests and assays in the market.

# In February 2018, Merck invested around USD 44 million (~EUR 40 million) for expanding its manufacturing and distribution centers in South Korea, India, and China.

# In August 2017, Hach (a subsidiary of Danaher Corporation) expanded its Loveland, US campus by inaugurating a new facility for R&D.

Asia Pacific is expected to witness the highest growth in the ATP assays market from 2019 to 2024

The global ATP assays market is segmented into five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. During the forecast period, the Asia Pacific market is estimated to grow at the highest CAGR, as several countries are witnessing a growing number of proteomics, genomics, and stem cell research activities, increasing research funding, rising investments by pharmaceutical & biotechnology companies, and the growing trend of research infrastructure modernization.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=223438780

Key Questions Addressed in the Report:

# Which are the top 10 players operating in the ATP assays market?

# What are the drivers, restraints, opportunities, and challenges of the market?

# What are the prevailing industry trends, and what is the current scenario in the market?

# What are the growth trends in the market at the segmental and overall levels?

# How is the market performing in different regions across the globe?

The prominent players in the global ATP assays market are Merck KGaA (Germany), Thermo Fisher Scientific, Inc. (US), PerkinElmer, Inc. (US), Lonza Group (Switzerland), Promega Corporation (US), Agilent Technologies, Inc. (US), Abcam plc. (UK), Danaher Corporation (US), Hygiena, LLC. (US), BioThema AB (Sweden), Abnova Corporation (Taiwan), AAT Bioquest (US), PromoCell GmbH (Germany), BioVision, Inc. (US), Geno Technology, Inc. (US), Biotium (US), Canvax Biotech S.L. (Spain), Creative Bioarray (US), Elabscience (US) and MBL International Corporation (US).

Technological Advancements in the Global Patient Blood Management Industry

The study involved four major activities to estimate the current size of the patient blood management market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Thereafter, market breakdown and data triangulation procedures were used to estimate the size of the segments and subsegments.

The global patient blood management market size is projected to reach USD 15.3 billion by 2024 from USD 10.7 billion in 2019, at a CAGR of 7.4% from 2019 to 2024. The rising prevalence of blood disorders and the increasing number of blood donations & blood donors will fuel market growth over the forecast period. Moreover, the rising prevalence of target diseases and technological advancements in the patient blood management industry will further fuel the growth of the market in the near future.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131352979

The blood transfusion segment of instruments to register significant growth over the forecast period

Based on product, the patient blood management market is segmented into instruments, accessories, reagents & kits, and software. The instrument segment is further sub-segmented into blood processing devices, blood transfusion devices, blood culture screening devices, diagnostic & testing instruments, and blood storage devices. Among these, the blood transfusion segment is anticipated to register significant growth over the forecast period. Growth in this segment is attributed to the upsurge in demand for blood components across the globe and the increase in government initiatives towards blood donation. In addition, newly approved indications for apheresis treatment such as acute disseminated encephalomyelitis, autoimmune hemolytic anemia, and cardiac neonatal lupus will further supplement the growth of this segment.

The whole blood segment is projected to hold the largest share of the market, by component, during the forecast period of 2019 to 2024

By component, the patient blood management market is segmented into whole blood and blood components. The whole blood segment is expected to hold a major share of the market during the forecast period. An increase in the number of surgical procedures coupled with rising incidences of blood-related disorders that require blood transfusion during treatment are the key factors supporting the market growth of this segment.

Recent Developments:

# In 2019, Abbott (US) received the US FDA approval for its ‘Alinity s’ blood culture screening system as well as the Afinion HbA1c Dx assay kit.

# In 2019, F. Hoffmann-La Roche LTD (Switzerland) received the US FDA approval for its cobas Babesia Test for donor screening.

# In 2018, Terumo BCT (Japan) and Stafa Cellular Therapy (US) entered into a collaborative agreement. Based on this agreement, Terumo BCT expands access to the StafaCT software to healthcare organizations.

# In 2018, B. Braun Melsungen AG (Ireland) acquired the bloodlines business of NxStage Medical, Inc. (US), which operates under the Medisystems brand.

# In 2018, Abbott (US) received a CE mark for its Alinity h-series to be used in the European Union

Blood banks were the key end users in the patient blood management market in 2019

On the basis of end users, the patient blood management market is segmented into hospitals and blood banks. The increasing number of blood donations has increased the need for proper management of blood. Blood banks are the key end users for various blood processing devices, blood collection devices, and blood storage devices. The key factors attributing to the growth of the blood banks segment include the growing awareness about blood donations, rising automation in blood banks, and the increase in the number of blood banks in developing countries.

The Asia Pacific region is expected to register significant growth during the forecast period of 2019-2024

The patient blood management market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The Asia Pacific blood management market is expected to register significant growth over the forecast period due to the modernization of healthcare infrastructure, increasing prevalence of chronic lifestyle diseases, and rising awareness about blood donation & blood safety. China accounted for a major share of the Asia Pacific market, owing to a large patient pool and favorable government guidelines to improve healthcare infrastructure in the country.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=131352979

Key Questions Addressed by the Report:

# What are the growth opportunities related to the adoption of patient blood management solutions across the globe in the future?

# Which product segment will register the highest adoption rate during the forecast period?

# Where will the advancements in products offered by various companies take the industry in the mid- to long-term?

# Emerging countries have immense opportunities for the growth of the market. Will this scenario continue in the next five years?

# Which end users are estimated to adopt patient blood management systems?

# What are the key strategies adopted by the key players operating in the market?

The major players in the market include Haemonetics Corporation (US), Fresenius SE & Co. KGaA (Germany), Terumo Corporation (Japan), Immucor, Inc. (US), B. Braun Melsungen AG (Ireland), Macopharma (US), bioMérieux SA (France), Asahi Kasei Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), Grifols, S.A. (Spain), F. Hoffmann-La Roche LTD (Switzerland), LivaNova PLC (UK), Danaher Corporation (US), Mediware Information Systems (US), Kawasumi Laboratories, Inc. (Japan), Haier Biomedical (China), Diatron (Hungary), and BAG Diagnostics GmbH (Germany), among others.

North American Healthcare IT Industry is Expecting Major Tech Revolutions by 2025

The study involved four major activities in estimating the size of the North America healthcare IT market. Exhaustive secondary research was done to collect information on the adoption of different technologies and their trends at the country level. Industry experts further validated the data obtained through secondary research through primary research.

Furthermore, the market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (country-level incidence data for various diseases) and top-down approach (assessment of utilization/adoption/penetration trends, by product and services, components, and end user). After that, market breakdown and data triangulation methods were used to estimate the size of segments and subsegments.

The North America healthcare IT market size is projected to reach USD 239.9 billion by 2025 from USD 96.3 billion in 2019, at a CAGR of 16.4% during the forecast period. Market growth can be attributed to the growing need to adhere to regulatory guidelines, government initiatives for eHealth, high return on investment (ROI), and rising need to curtail the escalating healthcare costs. However, the lack of in-house IT knowledge and reluctance among end-users to adopt new methods are expected to restrain the overall market growth to a certain extent during the forecast period.

Download PDF Brochure@

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=1190

Based on products and services, the healthcare providers segment accounted for the largest share of the North America healthcare IT market in 2018

Based on the products and services, the healthcare providers segment accounted for the largest share of the North American healthcare IT market in 2018. The large share of this segment is mainly attributed to the rising adoption of EHRs and other hospital information systems by healthcare providers, the inclination of the healthcare industry towards deployment of interoperable solutions, and growing regulatory requirements regarding patient information and safety. In this report, the healthcare provider solutions segment is segmented further into clinical solutions and non-clinical solutions. EHR, mHealth solutions, and PACS & VNA are some of the key clinical healthcare IT solutions covered in this report.

Target Audience:

# North American healthcare IT manufacturers

# North American healthcare IT distributors

# Healthcare payer companies

# Government associations

# Market research and consulting firms

# Venture capitalists and investors

By components, the services segment accounted for the largest share of the North America healthcare IT market in 2018

Based on components, the market is segmented into services, software, and hardware. In 2018, the services segment accounted for the largest share of the North American healthcare IT market. This is attributed to the introduction of complex software, the need for integration and interoperability of software, and the growing demand for consulting and outsourcing of various healthcare processes such as revenue cycle management, EHR management, pharmacy information management, and fraud detection.

Recent Developments:

# In 2019, Cerner Corporation launched the Next-generation cognitive health platform

# In 2019, GE Healthcare launched Edison Datalogue and my.Cryochain software

# In 2019, Cerner Corporation collaborated with Uniform Data System for Medical Rehabilitation to integrate their solutions that would help improve workflow for inpatient rehabilitation facilities.

# In 2019, Epic Systems partnered with Teledoc Health to integrate Teledoc Health’s virtual care platform to Epic’s App Orchard that would help the company conduct telehealth video visits.

Request Sample Pages@

https://www.marketsandmarkets.com/requestsampleNew.asp?id=1190

By end-users, the healthcare providers segment accounted for the largest share of the North America healthcare IT market in 2018

Based on end-users, the North American healthcare IT market is segmented into healthcare providers and healthcare payers. The healthcare providers segment is divided further into hospitals; ambulatory care centers; home healthcare agencies, nursing homes, and assisted living facilities; diagnostic and imaging centers; and pharmacies.

The healthcare payers segment is divided further into private payers and public payers. Hospitals form the largest end-user segment of the North American healthcare IT market, owing to the huge demand for various HCIT solutions among hospitals to manage the increasing load of patient information generated in hospitals and growing need to improve the quality of healthcare while improving operational efficiencies within organizations.

Key Questions Addressed in the Report

# Who are the top 10 players operating in the global North America healthcare IT market?

# What covers the drivers, restraints, opportunities, and challenges in the North America healthcare IT industry?

# What are the new technological advancements in the North America healthcare IT market?

# Comment on the regulatory scenario for the North America healthcare IT industry in various geographies.

# What are the growth trends in the North America healthcare IT market at the segmental and overall market levels?

Some of the prominent players operating in the North America healthcare IT market are McKesson Corporation (US), Oracle Corporation (US), GE Healthcare (US), Siemens Healthineers (Germany), Philips Healthcare (Netherlands), Athenahealth, Inc. (US), Infor, Inc. (US), Cognizant (US), Dell Technologies (US), and CVS Health (US).

You Can Also Read More Detailed Info@

https://www.marketsandmarkets.com/Market-Reports/north-america-healthcare-it-market-1190.html